文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Germline-targeting immunogens.

作者信息

Stamatatos Leonidas, Pancera Marie, McGuire Andrew T

机构信息

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Department of Global Health, University of Washington, Seattle, WA, USA.

出版信息

Immunol Rev. 2017 Jan;275(1):203-216. doi: 10.1111/imr.12483.


DOI:10.1111/imr.12483
PMID:28133796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5741082/
Abstract

In 2009, Dimitrov's group reported that the inferred germline (iGL) forms of several HIV-1 broadly neutralizing antibodies (bNAbs) did not display measurable binding to a recombinant gp140 Env protein (derived from the dual-tropic 89.6 virus), which was efficiently recognized by the mature (somatically mutated) antibodies. At that time, a small number of bNAbs were available, but in the following years, the implementation of high-throughput B-cell isolation and sequencing assays and of screening methodologies facilitated the isolation of greater numbers of bNAbs from infected subjects. Using these newest bNAbs, and a wide range of diverse recombinant Envs, we and others confirmed the observations made by Dimitrov's group. The results from these studies created a paradigm shift in our collective thinking as to why recombinant Envs are ineffective in eliciting bNAbs and has led to the "germline-targeting" immunization approach. Here we discuss this approach in detail: what has been done so far, the advantages and limitations of the current germline-targeting immunogens and of the animal models used to test them, and we conclude with a few thoughts about future directions in this area of research.

摘要

相似文献

[1]
Germline-targeting immunogens.

Immunol Rev. 2017-1

[2]
Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

J Virol. 2014-3

[3]
Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

PLoS Pathog. 2013-1-3

[4]
B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques.

PLoS Pathog. 2018-6-22

[5]
Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.

Immunol Rev. 2017-1

[6]
Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.

Immunity. 2015-11-17

[7]
A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins.

MAbs. 2011-7-1

[8]
Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.

Immunol Rev. 2017-1

[9]
'Immunization during ART and ATI for HIV-1 vaccine discovery/development'.

Curr Opin HIV AIDS. 2023-11-1

[10]
Characterization of the membrane-bound form of the chimeric, B/C recombinant HIV-1 Env, LT5.J4b12C.

J Gen Virol. 2018-8-21

引用本文的文献

[1]
Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes.

J Exp Med. 2025-10-6

[2]
Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial.

Proc Natl Acad Sci U S A. 2025-8-19

[3]
Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope.

NPJ Vaccines. 2025-8-5

[4]
The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies.

Nat Rev Microbiol. 2025-7-23

[5]
Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial.

bioRxiv. 2025-5-27

[6]
Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies.

PLoS Pathog. 2025-5-29

[7]
Mapping essential somatic hypermutations in a CD4-binding site bNAb informs HIV-1 vaccine design.

Cell Rep. 2025-5-27

[8]
Status of HIV vaccine development: progress and promise.

J Int AIDS Soc. 2025-5

[9]
Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-class antibodies.

bioRxiv. 2025-3-14

[10]
Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Vaccines (Basel). 2025-1-31

本文引用的文献

[1]
Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing.

Clin Transl Immunology. 2016-7-22

[2]
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.

Nature. 2016-7-28

[3]
Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Science. 2016-5-20

[4]
Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.

Sci Transl Med. 2016-4-27

[5]
HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.

Science. 2016-3-25

[6]
Structural basis for germline antibody recognition of HIV-1 immunogens.

Elife. 2016-3-21

[7]
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody.

Cell. 2016-4-7

[8]
Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer.

Science. 2016-3-4

[9]
Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.

Nat Commun. 2016-2-24

[10]
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.

Sci Transl Med. 2015-12-23

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索